{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:13:29Z","timestamp":1787170409719,"version":"build-2736575974"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jidinnovations.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JID Innovations"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.xjidi.2022.100095","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T12:34:16Z","timestamp":1642077256000},"page":"100095","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Cannabinoids for the Treatment of Dermatologic Conditions"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4805-0632","authenticated-orcid":false,"given":"Torunn E.","family":"Sivesind","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1121-2709","authenticated-orcid":false,"given":"Jalal","family":"Maghfour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4724-9570","authenticated-orcid":false,"given":"Hope","family":"Rietcheck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7284-0584","authenticated-orcid":false,"given":"Kevin","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5828-2974","authenticated-orcid":false,"given":"Ali S.","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8132-088X","authenticated-orcid":false,"given":"Robert P.","family":"Dellavalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xjidi.2022.100095_bib1","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.4049\/jimmunol.1102195","article-title":"Cannabinoid receptor 2 is critical for the homing and retention of marginal zone B lineage cells and for efficient T-independent immune responses","volume":"187","author":"Basu","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.xjidi.2022.100095_bib2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1124\/molpharm.120.000083","article-title":"Molecular mechanisms for the inflammation-resolving actions of Lenabasum","volume":"99","author":"Burstein","year":"2021","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.xjidi.2022.100095_bib3","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1021\/cn5000919","article-title":"TRP channel cannabinoid receptors in skin sensation, homeostasis, and inflammation","volume":"5","author":"Caterina","year":"2014","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.xjidi.2022.100095_bib4","doi-asserted-by":"crossref","first-page":"e224","DOI":"10.1111\/pde.13545","article-title":"Self-initiated use of topical cannabidiol oil for epidermolysis bullosa","volume":"35","author":"Chelliah","year":"2018","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.xjidi.2022.100095_bib5","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1136\/annrheumdis-2019-eular.6004","article-title":"AB0645 cannabinoids in the treatment of pain related to systemic sclerosis skin ulcers: our experience [abstract]","volume":"78","author":"Cocchiara","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.xjidi.2022.100095_bib6","first-page":"238","article-title":"Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin","volume":"52","author":"Dvorak","year":"2003","journal-title":"Inflamm Res Off J Eur Histamine Res Soc Al. Inflamm Res"},{"key":"10.1016\/j.xjidi.2022.100095_bib7","doi-asserted-by":"crossref","DOI":"10.5070\/D3246040706","article-title":"Cannabinoids in dermatology: a scoping review","volume":"24","author":"Eagleston","year":"2018","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.xjidi.2022.100095_bib8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1468-3083.2007.02351.x","article-title":"Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study)","volume":"22","author":"Eberlein","year":"2008","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.xjidi.2022.100095_bib9","first-page":"795","article-title":"Topical cannabinoids for the management of psoriasis vulgaris: report of a case and review of the literature","volume":"19","author":"Friedman","year":"2020","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.xjidi.2022.100095_bib11","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00213-011-2347-8","article-title":"Dronabinol, a cannabinoid agonist, reduces hair pulling in trichotillomania: a pilot study","volume":"218","author":"Grant","year":"2011","journal-title":"Psychopharmacol (Berlin)"},{"key":"10.1016\/j.xjidi.2022.100095_bib12","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/bjp.2008.324","article-title":"\u2018Entourage\u2019 effects of N -palmitoylethanolamide and N -oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors","volume":"155","author":"Ho","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.xjidi.2022.100095_bib13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1476-4598-12-86","article-title":"The complexity of NF-\u03baB signaling in inflammation and cancer","volume":"12","author":"Hoesel","year":"2013","journal-title":"Mol Cancer"},{"key":"10.1016\/j.xjidi.2022.100095_bib14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/art.39501","article-title":"The American College of Rheumatology provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis","volume":"68","author":"Khanna","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.xjidi.2022.100095_bib15","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s11481-013-9493-1","article-title":"Cannabinoids decrease the th17 inflammatory autoimmune phenotype","volume":"8","author":"Kozela","year":"2013","journal-title":"J\u00a0Neuroimmune Pharmacol"},{"key":"10.1016\/j.xjidi.2022.100095_bib16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pharmthera.2009.01.005","article-title":"The therapeutic potential of novel cannabinoid receptors","volume":"122","author":"Kreitzer","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.xjidi.2022.100095_bib17","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.xjidi.2022.100095_bib18","first-page":"1204","article-title":"An observational study of the application of a topical cannabinoid gel on sensitive dry skin","volume":"19","author":"Maghfour","year":"2020","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.xjidi.2022.100095_bib19","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jpainsymman.2017.06.005","article-title":"Topical medical cannabis: A new treatment for wound pain-three cases of pyoderma gangrenosum","volume":"54","author":"Maida","year":"2017","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.xjidi.2022.100095_bib20","doi-asserted-by":"crossref","first-page":"e14419","DOI":"10.1111\/dth.14419","article-title":"Promoting wound healing of uremic calciphylaxis leg ulcers using topical cannabis-based medicines","volume":"33","author":"Maida","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.xjidi.2022.100095_bib21","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/cpt.980","article-title":"Potent anti-inflammatory and pro-resolving effects of Anabasum in a human model of self-resolving acute inflammation","volume":"104","author":"Motwani","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xjidi.2022.100095_bib22","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1111\/j.1572-0241.2002.05852.x","article-title":"Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease","volume":"97","author":"Neff","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.xjidi.2022.100095_bib23","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.lfs.2015.12.053","article-title":"Ligands for cannabinoid receptors, promising anticancer agents","volume":"146","author":"Nikan","year":"2016","journal-title":"Life Sci"},{"key":"10.1016\/j.xjidi.2022.100095_bib24","first-page":"217","article-title":"Cannabis sativa as a Potential Treatment for Systemic Sclerosis","volume":"21","author":"Nogueira","year":"2019","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.xjidi.2022.100095_bib25","first-page":"e93","article-title":"A\u00a0therapeutic effect of cbd-enriched ointment in inflammatory skin diseases and cutaneous scars","volume":"170","author":"Palmieri","year":"2019","journal-title":"Clin Ter"},{"key":"10.1016\/j.xjidi.2022.100095_bib26","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/bph.13580","article-title":"The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations","volume":"174","author":"Petrosino","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.xjidi.2022.100095_bib27","first-page":"80","article-title":"Topical adelmidrol 2% emulsion, a novel aliamide, in the treatment of mild atopic dermatitis in pediatric subjects: a pilot study","volume":"15","author":"Pulvirenti","year":"2007","journal-title":"Acta Dermatovenerol Croat ADC"},{"key":"10.1016\/j.xjidi.2022.100095_bib28","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1016\/j.jid.2017.05.035","article-title":"Cannabinoid reduces inflammatory cytokines, tumor necrosis factor-\u03b1, and Type I interferons in dermatomyositis in\u00a0vitro","volume":"137","author":"Robinson","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2022.100095_bib29","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/bjd.17341","article-title":"Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: a report of three cases","volume":"180","author":"Schr\u00e4der","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2022.100095_bib30","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/annrheumdis-2018-eular.3512","article-title":"OP0006 Safety and efficacy of lenabasum (JBT-101) in diffuse cutaneous systemic sclerosis subjects treated for one year in an open-label extension of trial jbt101-ssc-001 [abstract]","volume":"77","author":"Spiera","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.xjidi.2022.100095_bib31","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1136\/annrheumdis-2019-eular.3390","article-title":"OP0325 safety and efficacy of lenabasum in an open-label extension of a phase 2 study in diffuse cutaneous systemic sclerosis subjects (DCSSC) [abstract]","volume":"78","author":"Spiera","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.xjidi.2022.100095_bib32","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/art.41294","article-title":"Safety and efficacy of Lenabasum in a Phase II, randomized, placebo-controlled trial in adults with systemic sclerosis","volume":"72","author":"Spiera","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.xjidi.2022.100095_bib33","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/annrheumdis-2017-eular.2712","article-title":"OP0126 A phase 2 study of safety and efficacy of anabasum (JBT-101) in systemic sclerosis [abstract]","volume":"76","author":"Spiera","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.xjidi.2022.100095_bib34","article-title":"Safety and efficacy of anabasum (JBT-101) in diffuse cutaneous systemic sclerosis (dcSSc) subjects treated in an open-label extension of trial jbt101-ssc-001","volume":"79","author":"Spiera","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.xjidi.2022.100095_bib35","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00105-006-1180-1","article-title":"Topische Cannabinoidagonisten. Eine effektive, neue M\u00f6glichkeit zur Behandlung von chronischem Pruritus [Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus]","volume":"57","author":"St\u00e4nder","year":"2006","journal-title":"Hautarzt Z Dermatol Venerol Verwandte Geb"},{"key":"10.1016\/j.xjidi.2022.100095_bib36","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jdermsci.2005.01.007","article-title":"Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin","volume":"38","author":"St\u00e4nder","year":"2005","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.xjidi.2022.100095_bib37","first-page":"97","article-title":"Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study","volume":"13","author":"Szepietowski","year":"2005","journal-title":"Acta Dermatovenerol Croat ADC"},{"key":"10.1016\/j.xjidi.2022.100095_bib38","series-title":"StatPearls [Internet]","article-title":"Cannaboinoid antiemetic therapy","author":"Taylor","year":"2020"},{"key":"10.1016\/j.xjidi.2022.100095_bib39","author":"Terry"},{"key":"10.1016\/j.xjidi.2022.100095_bib40","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1159\/000510896","article-title":"Efficacy and tolerability of a shampoo containing broad-spectrum cannabidiol in the treatment of scalp inflammation in patients with mild to moderate scalp psoriasis or seborrheic dermatitis","volume":"6","author":"Vincenzi","year":"2020","journal-title":"Skin Appendage Disord"},{"key":"10.1016\/j.xjidi.2022.100095_bib41","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2340\/00015555-2593","article-title":"Efficacy of body lotion containing N-palmitoylethanolamine in subjects with chronic pruritus due to dry skin: A Dermatocosmetic study","volume":"97","author":"Visse","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.xjidi.2022.100095_bib42","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/j.jid.2018.03.613","article-title":"605 Study of safety and efficacy of lenabasum, a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositis","volume":"138","author":"Werth","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2022.100095_bib43","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/annrheumdis-2019-eular.3397","article-title":"op 0241 safety and efficacy of lenabasum in an open-label extension of a phase 2 study of lenabasum in refractory skin-predominant dermatomyositis (dm) subjects [abstract]","volume":"78","author":"Werth","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.xjidi.2022.100095_bib44","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.2147\/CIA.S65448","article-title":"N-palmitoylethanolamine and N-acetylethanolamine are effective in asteatotic eczema: results of a randomized, double-blind, controlled study in 60 patients","volume":"9","author":"Yuan","year":"2014","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.xjidi.2022.100095_bib45","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1590\/S1516-44462006000200015","article-title":"History of cannabis as a medicine: a review","volume":"28","author":"Zuardi","year":"2006","journal-title":"Rev Bras Psiquiatr"}],"container-title":["JID Innovations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026722000017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026722000017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T08:03:16Z","timestamp":1763020996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667026722000017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S2667026722000017"],"URL":"https:\/\/doi.org\/10.1016\/j.xjidi.2022.100095","relation":{},"ISSN":["2667-0267"],"issn-type":[{"value":"2667-0267","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabinoids for the Treatment of Dermatologic Conditions","name":"articletitle","label":"Article Title"},{"value":"JID Innovations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xjidi.2022.100095","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}],"article-number":"100095"}}